TFXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
TELEFLEX INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$129.68−0.75 (-0.58%)
Close on Oct 19, 2026
- Market cap
- $5.66B
- P/E (TTM)
- –
- Dividend yield
- 1.05%
TELEFLEX INC revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asia | – | – | – | $305.97M | $281.35M | $320.73M | $202.35M | $357.81M | $352.70M | $352.38M | $214.76M | $337.06M | – | – |
| EMEA | – | – | – | $567.78M | $483.76M | $540.97M | $340.26M | $609.32M | $601.82M | $602.56M | $316.97M | $581.71M | – | – |
| Americas | – | – | – | $1.69B | $1.65B | $1.86B | $1.16B | $2.30B | $2.21B | $2.12B | $1.18B | $2.00B | – | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vascular | $1.03B | $1.01B | $917.73M | $996.22M | $986.09M | $941.29M | $903.51M | $863.11M | $852.14M | $844.82M | $841.11M | $707.78M | 45.8% | +4.8% |
| Interventional | $756.74M | $658.72M | $647.79M | $640.79M | $524.24M | $551.54M | $397.34M | $457.17M | $441.40M | $425.02M | $407.25M | $500.85M | 33.6% | +44.4% |
| Surgical | $417.24M | $407.89M | $418.16M | $396.91M | $385.78M | $394.32M | $404.87M | $399.12M | $400.18M | $394.83M | $388.33M | $428.23M | 18.5% | +8.2% |
| Other | – | – | – | $250.68M | $226.36M | $208.22M | -$6.18M | $217.25M | $238.52M | $272.76M | $75.75M | $297.23M | – | – |
| OEM | – | – | – | $308.40M | $310.55M | $320.70M | $344.51M | $341.65M | $341.41M | $336.71M | $326.01M | $317.11M | – | – |
| Anesthesia | – | – | – | $379.72M | $379.42M | $385.53M | $395.29M | $398.17M | $394.63M | $392.98M | $389.96M | $391.42M | – | – |
| Interventional urology | – | – | – | $303.98M | $315.60M | $322.32M | $331.09M | $339.21M | $329.43M | $324.15M | $319.79M | $315.97M | – | – |
By region
From the segment and revenue-disaggregation notes of Teleflex's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.